Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 27,872 | 25,488 | 25,225 | 27,172 | 27,148 |
| Cost of Goods | 1,177 | 958 | 770 | 979 | 1,250 |
| Gross Profit | 26,695 | 24,530 | 24,455 | 26,193 | 25,898 |
| Operating Expenses | 26,207 | 21,255 | 22,031 | 19,101 | 117,780 |
| Operating Income | 665 | 4,233 | 3,194 | 8,071 | -91,632 |
| Other Income | 107 | -303 | 2,841 | 4,410 | -8,646 |
| Pre-tax Income | 772 | 3,930 | 6,035 | 12,481 | -100,278 |
| Income Tax | 203 | 1,074 | 1,497 | 2,546 | 699 |
| Net Income Continuous | 569 | 2,856 | 4,538 | 9,935 | -100,977 |
| Minority Interests | 668 | 1,732 | 1,010 | 2,403 | 29 |
| Net Income | $-99 | $1,124 | $3,528 | $7,532 | $-101,006 |
| EPS Basic Total Ops | 0.00 | 0.01 | 0.04 | 0.09 | -1.54 |
| EPS Basic Continuous Ops | 0.00 | 0.03 | 0.05 | 0.12 | -1.54 |
| EPS Diluted Total Ops | N/A | 0.01 | 0.01 | 0.03 | -1.51 |
| EPS Diluted Continuous Ops | 0.01 | 0.03 | 0.04 | 0.10 | -1.49 |
| EPS Diluted Before Non-Recurring Items | 0.01 | 0.02 | 0.01 | N/A | N/A |
| EBITDA(a) | $1,165 | $4,678 | $3,422 | $8,486 | $-91,324 |